Literature DB >> 15149301

Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore.

Kang Sim1, Alex Su, Yiong Huak Chan, Naotaka Shinfuku, Ee Heok Kua, Chay Hoon Tan.   

Abstract

The purpose of the present study wa to determine the prevalence of antipsychotic polytherapy (use of more than one antipsychotic drug at one time) and its clinical correlates among 300 hospitalized psychotic Asian patients diagnosed with schizophrenia. It was hypothesized that such treatment would be associated with more severe illness than in comparable monotherapy patients, and with higher chlorpromazine-equivalent (CPZ) total daily doses. Clinical and demographic details were obtained from the medical records and direct clinical examinations. Polytherapy was encountered in 215 of the 300 patients (71.7%), with an average number of 1.8 antipsychotics (range 1-4) prescribed at a mean CPZ daily dose of 612 +/- 528 mg (median: 464 mg, range: 25-2500 mg). The 215 patients prescribed more than one antipsychotic agents were younger, ill longer, more likely to be taking at least one high-potency agent, in receipt of higher average daily CPZ doses, and more likely to be prescribed anticholinergic agents but with similar admission illness severity rating (Brief Psychiatric Rating Scale) scores compared to the 85 patients given only one antipsychotic drug at one time. The high rate of antipsychotic polytherapy that appeared to be unrelated to current illness severity suggests that this practice may not consistently be based on rational therapeutic principles.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149301     DOI: 10.1111/j.1440-1819.2004.01239.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  4 in total

1.  Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis.

Authors:  Lone Baandrup; Jan Sørensen; Henrik Lublin; Merete Nordentoft; Birte Glenthoj
Journal:  Eur J Health Econ       Date:  2011-03-31

2.  Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.

Authors:  Taishiro Kishimoto; Koichiro Watanabe; Hiroyuki Uchida; Masaru Mimura; John M Kane; Christoph U Correll
Journal:  Psychiatry Res       Date:  2013-04-18       Impact factor: 3.222

3.  Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan.

Authors:  Wenyu Ye; Haya Ascher-Svanum; Jennifer A Flynn; Yuka Tanji; Michihiro Takahashi
Journal:  Clinicoecon Outcomes Res       Date:  2012-01-13

4.  Prevalence of Antipsychotic Polypharmacy and Associated Factors among Outpatients with Schizophrenia Attending Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia.

Authors:  Siranesh Tesfaye; Nigussie Debencho; Teresa Kisi; Minale Tareke
Journal:  Psychiatry J       Date:  2016-01-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.